ICYMI: Opdivo Now Approved for Patients Aged 12+ with Surgically Resected Stage 2B-C Melanoma

  In the past, the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) for different forms of cancer, such as non-small cell lung cancer (NSCLC) and melanoma. More recently,…

Continue Reading ICYMI: Opdivo Now Approved for Patients Aged 12+ with Surgically Resected Stage 2B-C Melanoma
Rare Community Profiles: Melanoma Research Alliance’s Marc Hurlbert Shares Milestone Achievement of RARE Registry for Acral and Mucosal Melanoma
Photo courtesy of the Melanoma Research Alliance

Rare Community Profiles: Melanoma Research Alliance’s Marc Hurlbert Shares Milestone Achievement of RARE Registry for Acral and Mucosal Melanoma

Rare Community Profiles     Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…

Continue Reading Rare Community Profiles: Melanoma Research Alliance’s Marc Hurlbert Shares Milestone Achievement of RARE Registry for Acral and Mucosal Melanoma
A Preview of Potentially Historic FDA Approvals for 2023
source: shutterstock.com

A Preview of Potentially Historic FDA Approvals for 2023

  The later part of 2023 will see decisions on drugs in four areas such as advanced melanoma, sickle cell disease, Alzheimer’s disease, and depression. BioSpace shines the spotlight on…

Continue Reading A Preview of Potentially Historic FDA Approvals for 2023
Could Melanoma Drugs be Effective in Treating Papillary Craniopharyngioma (PCP)?
source: pixabay.com

Could Melanoma Drugs be Effective in Treating Papillary Craniopharyngioma (PCP)?

  Each year, there are less than 600 new cases of papillary craniopharyngioma (PCP) diagnosed within the United States. While PCP typically has a good prognosis with treatment, treatment is…

Continue Reading Could Melanoma Drugs be Effective in Treating Papillary Craniopharyngioma (PCP)?
INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 3)
https://pixabay.com/en/american-football-football-sports-1666276/

INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 3)

Before you read on, make sure to check out: Part 1 of our article: Green Bay Packers' Shemar Jean-Charles and Los Angeles Chargers' Storm Norton discuss why they raise Alzheimer's disease…

Continue Reading INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 3)

The European Commission Has Approved Pembrolizumab (Keytruda) to Treat Resected Stage IIB and IIC Melanoma

According to a press release by Merck & Co. issued on June 24, the European Commission has approved the use of adjuvant Pembrolizumab to treat resected stage IIB/C melanoma. "Adjuvant"…

Continue Reading The European Commission Has Approved Pembrolizumab (Keytruda) to Treat Resected Stage IIB and IIC Melanoma
An Innocent-Looking Shadow on Her Thumbnail Turned Out to be Subungual Melanoma
Source: https://pixabay.com/en/thumb-up-like-sign-hand-ok-good-441938/

An Innocent-Looking Shadow on Her Thumbnail Turned Out to be Subungual Melanoma

Maria’s message is: “when in doubt, get a biopsy." Ten years ago, Maria Sylvia noticed a vertical streak on her thumbnail that at the time she thought was “cool." She…

Continue Reading An Innocent-Looking Shadow on Her Thumbnail Turned Out to be Subungual Melanoma
Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up
source: pixabay.com

Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up

  According to a recent report in the Journal of Clinical Oncology, over one thousand patients with high-risk stage III melanoma were included in the Keynote-054 clinical trial (NCT02362594). The…

Continue Reading Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up